When given the option to prolong hormone-based breast cancer treatment, many patients chose to, new research finds.
A new study led by University of Michigan Health Rogel Cancer Center and Stanford Medicine scientists concluded:
· Nearly half of early-stage breast cancer patients (47%) decided to extend their treatment to 10 years after finishing five.
· 62% of stage 2 patients said they would extend their treatment.
· 39% of stage 1 patients were willing to prolong treatment.
· Physician recommendation was a deciding factor for many women.
· Fear of recurrence was also a deciding factor.
